IRF9 and neoplasm: The expression of IRF9 mid-chemotherapy was associated with risk of distant relapse (Fig. 3d), whereby patients with low tumor IRF9 expression mid-chemotherapy were over seven times more likely to develop metastatic relapse than patients with high tumor IRF9 expression (Fig. 3d).